Bremelanotide
Also known as: Vyleesi, PT-141
Classification
Peptide
Regulatory Status
FDA-approved prescription product or labeled drug class
Sources
1
Review
n/a
Overview
Bremelanotide is represented by its commonly described melanocortin receptor agonist mechanism. This conservative launch record supports search and overlap detection, not medical recommendation.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-approved melanocortin agonist (Vyleesi) studied and labeled for acquired, generalized hypoactive sexual desire disorder in premenopausal women, as an on-demand subcutaneous injection per product labeling.
Interactions & cautions
Drug interactions
oral naltrexone-containing products — May significantly decrease oral naltrexone exposure due to slowed gastric emptying—see full label. (high)
antihypertensive regimens — Additive blood-pressure effects require clinical review given labeled BP increases after dosing. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw